Initial Experience With CMC-544 (Inotuzumab Ozogamicin) in Pediatric Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Pediatric Blood and Cancer - United States
doi 10.1002/pbc.24721
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States

PharmacoEconomics
Health PolicyPublic HealthOccupational HealthPharmacologyEnvironmental
2019English

Pcn142 - Cost-Effectiveness Analysis of Inotuzumab Ozogamicin for the Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in Bulgaria

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Feasibility of Allografting in Patients With Advanced Acute Lymphoblastic Leukemia After Salvage Therapy With Inotuzumab Ozogamicin

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2013English

Pcn71 - Budget Impact Analysis of Inotuzumab Ozogamicin for the Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in Bulgaria

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia

Advances in Therapy
MedicinePharmacology
2019English

Assessment of Clinical Immunogenicity of Inotuzumab Ozogamicin in Patients With Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia

AAPS Open
2018English

Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE

Cancer
Cancer ResearchOncology
2018English

Pcn146 - Inotuzumab Ozogamicin in Patients With Relapsed or Refractory (R/R) Acute Lymphocytic Leukemia (All): Establishing a Value-Based Cost – Preliminary Results

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcn170 - Cost-Effectiveness of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Canadian Societal Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy